Get the Stockscreener App
4.22
31.46%
1.01
Neonc Technologies Holdings Inc stock is traded at $4.22, with a volume of 639.85K.
It is up +31.46% in the last 24 hours and up +14.67% over the past month.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
See More
Previous Close:
$3.21
Open:
$3.22
24h Volume:
639.85K
Relative Volume:
5.25
Market Cap:
$109.45M
Revenue:
$40,000
Net Income/Loss:
$-38.64M
P/E Ratio:
-2.2917
EPS:
-1.8414
Net Cash Flow:
$-22.21M
1W Performance:
+20.57%
1M Performance:
+14.67%
6M Performance:
-58.79%
1Y Performance:
-18.69%
1-Day Range:
$3.18
$4.3277
1-Week Range:
$3.13
$4.74
52-Week Range:
$3.005
$12.99
Neonc Technologies Holdings Inc Stock (NTHI) Company Profile
Name
Neonc Technologies Holdings Inc
Sector
Industry
Phone
310 663 7831
Address
23975 PARK SORRENTO, CALABASAS
Compare NTHI vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTHI
Neonc Technologies Holdings Inc
|
4.22 | 89.74M | 40,000 | -38.64M | -22.21M | -1.8414 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Neonc Technologies Holdings Inc Stock (NTHI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-26 | Initiated | Alliance Global Partners | Buy |
| May-18-26 | Initiated | Maxim Group | Buy |
| Apr-24-26 | Initiated | BTIG Research | Buy |
Neonc Technologies Holdings Inc Stock (NTHI) Latest News
NTHI: All proposals, including director elections and plan amendments, were approved without questions - TradingView
NeOnc Reports 26.1-Month Median Overall Survival in Phase 2a Brain Cancer Trial - Minichart
Form 8K Neonc Technologies Holdings Inc For: 13 August By Investing.com - Investing.com Canada
NeOnc Technologies holds investor call to discuss Phase 2a NEO100-01 results By Investing.com - Investing.com
NeOnc Technologies (NTHI) Reports Positive NEO100 Phase 2a Results, Plans FDA Type B Meeting - Kalkine Media
The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech - The Manila Times
NeOnc Technologies Holdings’ NEO100 Phase 2a Results Highlight Intranasal Brain-Delivery Platform Potential - Quiver Quantitative
Why is Neonc Technologies stock surging today? By Investing.com - Investing.com South Africa
NeOnc Technologies Holdings, Inc. Common Stock (NASDAQ: NTHI) Stock Price, News & Analysis - Kalkine
Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer - The Manila Times
NeOnc Technologies Holdings Reports Positive Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma - Quiver Quantitative
NeOnc Technologies shares jump after positive Phase 2a glioma results - Yahoo Finance
NeOnc Technologies Reports Phase 2a NEO100 Trial in Recurrent Glioma Surpasses Historical Progression-Free Survival by Nearly 2.5x - Kalkine Media
Why is Neonc Technologies stock surging today? - Investing.com
NeOnc Technologies Reports Positive Phase 2a Glioma Results - TipRanks
Form 8K Neonc Technologies Holdings Inc For: 12 August By Investing.com - Investing.com India
NeOnc reports phase 2a glioma trial meets primary endpoint By Investing.com - Investing.com Australia
NeOnc reports phase 2a glioma trial meets primary endpoint - Investing.com
NeOnc Technologies stock jumps on positive glioma trial data - Investing.com
NeOnc Technologies Reports Positive Phase 2a NEO100 Results; Median OS 26.09 Months, PFS-6 48.9% - TradingView
Why is NeOnc Technologies stock surging today? By Investing.com - Investing.com Canada
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma - The Manila Times
Five of 24 glioma patients remain on NeOnc’s at-home nasal therapy - Stock Titan
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence - TMX Newsfile
$NeOnc Technologies (NTHI.US)$@Trytosaveabit and thats 10% ROI! thanks for the heads-up! [Cool Guy] - Moomoo
NeOnc to Present Topline Phase 2a NEO100 Glioma Data on August 12 - Minichart
NeOnc to present phase 2a NEO100 trial results on Tuesday By Investing.com - Investing.com UK
NeOnc to present phase 2a trial results Wednesday By Investing.com - Investing.com Nigeria
NeOnc Highlights Q2 Results and CNS Oncology Progress - TipRanks
NeOnc Q2 Net Loss Widens to $14.2 Million - Quiver Quantitative
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma - NewsBreak: Local News & Alerts
NeOnc Technologies Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Duos Technologies Group Sets Second Quarter 2026 Earnings Call for Monday, August 17, 2026 at 4:30 PM ET - Stocktwits
NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears - The Manila Times
NeOnc to present phase 2a NEO100 trial results on Tuesday - Investing.com
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout - Stocktwits
NEONC TECHNOLOGIES HOLDINGS, INC. Q2 2026: Revenue $0 EPS $(0.58) — 10-Q Summary - TradingView
NTHI: Q2 2026 net loss was $14.2M; liquidity remains a concern despite $20.1M raised in H1 2026 - TradingView
NeOnc Technologies (NTHI) raises $20M but warns on going concern - Stock Titan
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout - GlobeNewswire Inc.
NeOnc Technologies Holdings to Host Investor Call on Phase 2a Topline Results for NEO100-01 Trial - Quiver Quantitative
NTHI Stock Price and Chart — NASDAQ:NTHI - TradingView
NeOnc Technologies Holdings Inc (NTHI) Stock News Today - TradingKey
NeOnc Technologies Holdings Inc (NTHI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NTHI|NeOnc Technologies Holdings Inc|Price:3.430| - TradingKey
NeOnc Technologies Holdings Inc (NTHI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neonc Technologies Holdings, Inc. Announces Appointment of Nasim Shomali to Board of Directors, Effective July 1, 2026 - marketscreener.com
NeOnc Technologies Holdings, Inc. Revenue Breakdown – NASDAQ:NTHI - TradingView
Neonc Technologies Appoints Strategy And Finance Executive Nasim Shomali To Its Board Of Directors - Menafn
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors - Asianet Newsable
NeOnc appoints Nasim Shomali to board of directors - Investing.com
Neonc Technologies Holdings Inc Stock (NTHI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):